U.S. patent application number 16/406163 was filed with the patent office on 2019-08-29 for elongated tissue matrices.
The applicant listed for this patent is LifeCell Corporation. Invention is credited to Nathaniel Bachrach, Benjamin T. Kibalo, Timothy Roock.
Application Number | 20190262121 16/406163 |
Document ID | / |
Family ID | 47664424 |
Filed Date | 2019-08-29 |
![](/patent/app/20190262121/US20190262121A1-20190829-D00000.png)
![](/patent/app/20190262121/US20190262121A1-20190829-D00001.png)
![](/patent/app/20190262121/US20190262121A1-20190829-D00002.png)
![](/patent/app/20190262121/US20190262121A1-20190829-D00003.png)
![](/patent/app/20190262121/US20190262121A1-20190829-D00004.png)
![](/patent/app/20190262121/US20190262121A1-20190829-D00005.png)
![](/patent/app/20190262121/US20190262121A1-20190829-D00006.png)
![](/patent/app/20190262121/US20190262121A1-20190829-D00007.png)
![](/patent/app/20190262121/US20190262121A1-20190829-D00008.png)
![](/patent/app/20190262121/US20190262121A1-20190829-D00009.png)
![](/patent/app/20190262121/US20190262121A1-20190829-D00010.png)
View All Diagrams
United States Patent
Application |
20190262121 |
Kind Code |
A1 |
Roock; Timothy ; et
al. |
August 29, 2019 |
Elongated Tissue Matrices
Abstract
Elongated and high aspect ratio tissue treatment products are
provided. Methods of making and using the tissue treatment products
are also provided. The tissue treatment products can be used as
implants that conform to the site of implantation and resist
migration away from their implantation site in vivo.
Inventors: |
Roock; Timothy; (Bordentown,
NJ) ; Bachrach; Nathaniel; (Clifton, NJ) ;
Kibalo; Benjamin T.; (Columbia, MD) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
LifeCell Corporation |
Madison |
NJ |
US |
|
|
Family ID: |
47664424 |
Appl. No.: |
16/406163 |
Filed: |
May 8, 2019 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15003187 |
Jan 21, 2016 |
10327884 |
|
|
16406163 |
|
|
|
|
13743962 |
Jan 17, 2013 |
9271821 |
|
|
15003187 |
|
|
|
|
61590035 |
Jan 24, 2012 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61L 27/50 20130101;
A61L 27/3604 20130101; A61L 2430/40 20130101; A61L 2430/04
20130101; A61L 2300/64 20130101; A61L 27/3683 20130101; A61L 27/362
20130101; A61F 2/02 20130101; A61L 2400/06 20130101; A61L 27/38
20130101; A61L 27/54 20130101 |
International
Class: |
A61F 2/02 20060101
A61F002/02; A61L 27/50 20060101 A61L027/50; A61L 27/36 20060101
A61L027/36; A61L 27/38 20060101 A61L027/38; A61L 27/54 20060101
A61L027/54 |
Claims
1. A method of making a tissue treatment product, comprising:
selecting a tissue; decellularizing the tissue fully or partially
to produce an acellular tissue matrix; and further processing the
acellular tissue matrix to form a collection of loosely arranged
elongated elements, each elongated element having a length
dimension, a width dimension, and a height dimension, and wherein
each elongated element has an aspect ratio greater than 50:1.
2. The method of claim 1, wherein each elongated element is in the
form of a cylinder.
3. The method of claim 2, wherein each cylinder is frozen,
freeze-dried, desiccated, or partially crosslinked to preserve a
cylindrical shape.
4. The method of claim 2, wherein processing the acellular tissue
matrix to form a collection of loosely arranged elongated elements,
comprises forming a rolled cylinder and slicing the rolled cylinder
across a circular face or along a long axis of the cylinder to
produce the elongated elements.
5. The method of claim 1, wherein at least one of a human, a
nonhuman primate, a pig, a cow, a horse, a goat, a sheep, a dog, a
cat, a rabbit, a guinea a pig, a gerbil, a hamster, a rat, or a
mouse tissue is used to prepare the partially or fully
decellularized tissue matrix.
6. The method of claim 1, wherein the tissue is porcine tissue.
7. The method of claim 1, wherein the tissue is dermal tissue.
8. The method of claim 1, further comprising removing
alpha-galactose moieties from the tissue treatment product.
9. The method of claim 1, wherein a tissue source for the tissue
does not express alpha-galactose epitopes.
10. The method of claim 1, wherein the collection of loosely
arranged elongated elements are configured to be implanted into an
anatomical site such that the tissue matrix is in direct contact
with surrounding native tissue thereby allowing cellular ingrowth
and tissue integration.
Description
[0001] This application is a divisional application of U.S. patent
application Ser. No. 15/003,187 filed Jan. 21, 2016, which is a
continuation application of U.S. patent application Ser. No.
13/743,962, filed Jan. 17, 2013, which claims priority to U.S.
Provisional Application No. 61/590,035, filed Jan. 24, 2012, all
applications named above of which are incorporated herein by
reference in their entirety.
[0002] The present disclosure relates generally to methods of
making and using elongated tissue matrices, and more particularly,
to methods of making and using tissue matrices having a high aspect
ratio.
[0003] Various tissue-derived products are used to repair,
regenerate, heal, or otherwise treat diseased or damaged tissues
and organs. Such products can include intact tissue grafts and/or
partially or completely decellularized tissues. These tissue
treatment products generally have a shape that is defined by their
tissue of origin. For example, dermal or intestinal products will
generally comprise sheets of relatively flexible materials.
However, not all wounds, voids, and/or other tissue treatment sites
are amenable to treatment with tissue matrices in the form of a
sheet. For example, a potential drawback of using sheet material is
the inability to fully conform the sheet to the shape of the void,
wound, or tissue being treated. Similarly, treatment with
injectable materials (e.g. a non-sheet of particulate material
delivered via syringe) may also be potentially challenging in cases
where the injectable matrix has a tendency to migrate away from the
void, wound, or tissue being treated. This migration could be a
concern cosmetically and/or physiologically.
[0004] In order to treat, repair, heal or regenerate certain tissue
or organ defects, it may be desirable to use materials capable of
maintaining shapes or configurations that more closely conform to
the anatomic structures to be treated and that reduce the rate of
migration away from the implant site. Accordingly, disclosed herein
are methods of producing elongated acellular tissue matrices that
can be used to fill a void, wound, or other space in tissue in need
of treatment, repair, healing, or regeneration. The elongated
tissue matrices can be molded to fill a desired shape, while also
reducing the risk that the implant will migrate away from the
implant site. Also disclosed herein are methods of treatment using
such matrices.
DESCRIPTION OF THE DRAWINGS
[0005] FIG. 1 is a photograph of an acellular tissue treatment
product according to certain embodiments of the present
disclosure.
[0006] FIG. 2 shows calculated ultrasound volumes (measured in
cubic centimeters) for certain tissue treatment products four weeks
after implantation in a Yucatan minipig mammary gland, as described
in example 2.
[0007] FIG. 3 is a plot of ultrasound volume (measured in cubic
centimeters) against dry tissue mass for certain tissue treatment
products, measured four weeks after implantation in a Yucatan
minipig mammary gland, as described in example 2.
[0008] FIG. 4 is an ultrasound calibration analysis that was
performed by comparing the calculated ultrasound volume immediately
after implantation with the actual volumes of implanted material,
as described in example 2.
[0009] FIG. 5 is a graph showing the results of indentation
tonometry assays conducted on certain tissue treatment products
four weeks after implantation in a Yucatan minipig mammary gland,
as described in example 2. A larger value indicates a softer (more
compliant) implant site, while a lower value indicates a harder
(less compliant) implant site.
[0010] FIG. 6 compares indentation tonometry results for certain
tissue treatment products that were implanted in a Yucatan minipig
mammary gland, as described in example 2. Tonometry results are
plotted at time T=0 and T=4 weeks.
[0011] FIG. 7 is a plot of stiffness values for certain tissue
treatment products that were implanted in a Yucatan minipig mammary
gland, as measured by BTC-2000.TM. (SRLI Technologies, Nashville,
Tenn.), as described in example 2.
[0012] FIG. 8 is a photograph of a raised mammary gland four weeks
after implantation of a representative tissue treatment product in
a Yucatan minipig mammary gland, as described in example 2.
[0013] FIG. 9 is a plot of dimple depth, as measured by non-load
tonometry, for certain tissue treatment products four weeks after
implantation in a Yucatan minipig mammary gland, as described in
example 2.
[0014] FIGS. 10A-10B show X-ray imaging of a Yucatan minipig
mammary gland before surgery (FIG. 10A) and four weeks after
implantation of tissue treatment products (FIG. 10B), as described
in example 2.
[0015] FIG. 11 is a photograph showing the gross anatomical
structure of a high aspect ratio tissue treatment product (in PBS)
four weeks after implantation in a Yucatan minipig mammary gland,
as described in example 2.
[0016] FIG. 12 is a photograph showing the gross anatomical
structure of a high aspect ratio tissue treatment product (in a
preservative solution) four weeks after implantation in a Yucatan
minipig mammary gland, as described in example 2.
[0017] FIG. 13 shows H&E staining of a high aspect ratio tissue
treatment product (in PBS) four weeks after implantation in a
Yucatan minipig mammary gland, as described in example 2.
[0018] FIG. 14 shows H&E staining of a high aspect ratio tissue
treatment product (in a preservative solution) four weeks after
implantation in a Yucatan minipig mammary gland, as described in
example 2.
[0019] FIGS. 15A-15C shows histology scoring of H&E stained
tissue treatment products four weeks after implantation in a
Yucatan minipig mammary gland, as described in example 2. Tissue
treatment products were scored for fibroblasts (FIG. 15A),
revascularization (FIG. 15B), and inflammation (FIG. 15C).
[0020] FIG. 16 compares ultrasound volume (measured in cubic
centimeters) for certain tissue treatment products four weeks and
twelve weeks after implantation in a Yucatan minipig mammary gland,
as described in example 2.
[0021] FIGS. 17A and B provide a comparison of raised or dimpled
implants containing certain tissue treatment products four weeks
(FIG. 17A) and twelve weeks (FIG. 17B) after implantation in a
Yucatan minipig mammary gland, as described in example 2.
[0022] FIG. 18 shows H&E staining of a high aspect ratio tissue
treatment product (in PBS) twelve weeks after implantation in a
Yucatan minipig mammary gland, as described in example 2.
[0023] FIG. 19 shows H&E staining of a high aspect ratio tissue
treatment product (in a preservative solution) twelve weeks after
implantation in a Yucatan minipig mammary gland, as described in
example 2.
[0024] FIGS. 20A, 20B and 20C show histology scoring of H&E
stained tissue treatment products four weeks and twelve weeks after
implantation in a Yucatan minipig mammary gland, as described in
example 2. Tissue treatment products were scored for fibroblasts
(FIG. 20A), revascularization (FIG. 20B), and inflammation (FIG.
20C).
DESCRIPTION OF CERTAIN EXEMPLARY EMBODIMENTS
[0025] Reference will now be made in detail to certain exemplary
embodiments according to the present disclosure, certain examples
of which are illustrated in the accompanying drawings.
[0026] Disclosed herein are tissue treatment products. In various
embodiments, a tissue treatment product comprises a collection of
elongated elements, each elongated element comprising a tissue
matrix that has been at least partially decellularized, and wherein
each elongated element has a flexible three-dimensional structure
comprising a length dimension, a width dimension, and a height
dimension, and wherein one dimension is substantially larger than
the other two dimensions (e.g., at least about 2, 3, 4, 5, 10, 20,
50, or 100 times larger, or any value in between). In some
embodiments, the tissue treatment products can be used as implants
that will conform to the anatomical shape of an implant site while
resisting migration away from the site of implantation and/or
avoiding significant hardening or raising/swelling of the implant
(e.g., due to inflammation and/or the formation of granulation or
scar tissue around the implant), as compared to an implanted tissue
treatment product that does not comprise elongated or high aspect
ratio elements. For example, a hardened and/or raised subcutaneous
implant may be cosmetically undesirable or may result in
complications that necessitate implant removal.
[0027] Various human or other animal tissues and various methods
can be used to prepare tissue treatment products. For example, the
compositions can be prepared by selecting a human or porcine
tissue; decellularizing the tissue to produce a collagen-containing
tissue matrix; and applying mechanical forces (e.g., rolling,
freezing, and/or cutting acellular tissue) to produce an elongated
tissue matrix. For example, one or more sheets of acellular tissue
matrix can be rolled into a cylindrical structure of desired length
and diameter, frozen, and then optionally sliced, (e.g., on a deli
slicer) to produce tissue treatment products whose elements have a
high aspect ratio structure. Elongated elements or high aspect
ratio elements can comprise a structure having a length dimension,
a width dimension, and a height dimension, and wherein one
dimension is substantially larger than the other two dimensions
(e.g., at least about 2, 3, 4, 5, 10, 20, 50, or 100 times larger,
or any value in between).
[0028] The compositions produced in this manner can be used, in
certain embodiments, to regenerate, repair, heal, augment,
reinforce, and/or treat tissues that have been damaged or lost due
to various diseases and/or structural damage (e.g., from trauma,
surgery, atrophy, and/or long-term wear and degeneration). In some
embodiments, the elongated tissue matrices can be folded,
compressed, or otherwise molded to fill a desired anatomical shape
at a site of implantation. In some embodiments, the elongated
elements are capable of being included within a syringe or similar
device for injection into an implant. In certain embodiments, the
ability of elongated tissue matrices to fill an anatomical space
allows for the more preservation of a more natural look or feel
after implantation (i.e., a more natural look or feel after
completion of the implantation surgery and/or after natural healing
following implantation). Furthermore, in various embodiments, the
elongated elements of these tissue treatment products resist
migration away from the implant site, while also allowing for
continued fluid passage and preventing fluid buildup at the implant
site. Further, in some embodiments the elongated elements avoid
significant hardening or raising/swelling of the implant (e.g., due
to inflammation and/or the formation of granulation or scar tissue
around the implant), as compared to an implanted tissue treatment
product that does not comprise elongated or high aspect ratio
elements.
[0029] The compositions of the present disclosure can also be used,
in certain embodiments, for cosmetic purposes to repair or alter
the appearance or feel of a native tissue. In some embodiments,
elongated tissue treatment products can be folded, compressed, or
otherwise molded to fill a space between separated tissues,
regardless of the shape of the space. In various embodiments, the
compositions will not migrate away from the site of implantation
while also allowing for continued fluid passage and preventing
fluid buildup at the implant site.
[0030] The materials and methods provided herein can be used to
make a biocompatible implant. As used herein, a "biocompatible"
composition is one that has the ability to support the migration
and proliferation of native cells from surrounding tissue into an
implanted tissue treatment product. Biocompatible compositions
support native cellular activity necessary for tissue regeneration,
repair, healing, or treatment and do not elicit a substantial
immune response that prevents such cellular activity. As used
herein, a "substantial immune response" is one that prevents
partial or complete tissue regeneration, repair, healing, or
treatment.
[0031] As used herein, the terms "native cells" and "native tissue"
mean the cells or tissue present in the recipient organ or tissue
prior to implantation of a tissue treatment product, or the cells
or tissue produced by the host animal after implantation.
[0032] The section headings used herein are for organizational
purposes only and are not to be construed as limiting the subject
matter described. All documents, or portions of documents, cited in
this application, including but not limited to patents, patent
applications, articles, books, and treatises, are hereby expressly
incorporated by reference in their entirety for any purpose. To the
extent publications and patents or patent applications incorporated
by reference contradict the invention contained in the
specification, the specification will supersede any contradictory
material.
[0033] In this application, the use of the singular includes the
plural unless specifically stated otherwise. Also in this
application, the use of "or" means "and/or" unless stated
otherwise. Furthermore, the use of the term "including," as well as
other forms, such as "includes" and "included," are not limiting.
Any range described here will be understood to include the
endpoints and all values between the endpoints.
Tissue Treatment Compositions
[0034] In certain embodiments, a tissue treatment product is
provided. As used herein, a "tissue treatment product" comprises
human or animal tissue that has been at least partially
decellularized. Tissue treatment products can contain tissue that
is acellular, partially decellularized, and/or decellularized
tissue that has been repopulated with exogenous cells, so long as
the tissue retains at least some of the extracellular matrix
scaffold found in native tissue prior to decellularizing.
[0035] In some embodiments, the tissue treatment products are
processed such that they can conform to the shape of an anatomical
implant site. It may be beneficial to conform the shape of the
tissue matrices to the desired shape of the anatomical site in a
way that is not easily done with a sheet of acellular tissue.
Various processes are known to alter the three-dimensional shape of
a sheet of acellular tissue, but some of these can also alter the
tissue matrix in undesirable ways. For example, chemical
cross-linking can be used to alter the three-dimensional structure
an acellular tissue matrix, but excessive cross-linking can also
alter the biological properties of the tissue, and chemical
cross-linking agents may be harmful to patients when implanted in a
patient. Accordingly, alternative methods for controlling the shape
of tissue treatment products, while preventing migration of the
products away from an implant site, would be beneficial and are
disclosed herein.
[0036] In certain embodiments, a tissue treatment product comprises
a collection of elongated elements or subunits (hereafter referred
to as an "elongated tissue treatment product"). In some
embodiments, each elongated element comprises a tissue matrix that
has been at least partially decellularized, and each elongated
element has a flexible three-dimensional structure comprising a
length dimension, a width dimension, and a height dimension, and
wherein one dimension (i.e., the "long axis") is substantially
larger than the other two dimensions. The term "substantially" in
this context means having a dimension that is at least 10% longer
than either of the two remaining dimensions. In some embodiments,
the elongated element is at least about 10%, 15%, 20%, 25%, 30%,
35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 100%, 150%, 200%,
250%, 300%, 350%, 400%, 450%, 500%, 750%, 1000%, 2000% or 5000% (or
any percentage in between) longer in one dimension. The elongated
element can be regular (e.g., an ellipsoid, cylinder, rectangular
cuboid, etc.) or irregular (i.e., lacking in uniform structure but
generally having one elongated axis). In certain embodiments, the
elongated element is in the form of a cylinder prepared from one or
more (e.g., 1, 2, 3, 4, 5, 10, 20, or more) rolled pieces or sheets
of acellular tissue. The cylinder of rolled acellular tissue can be
held in place through natural adhesion, or by freezing,
freeze-drying, desiccating, or by any other method of fixing the
acellular tissue that is known in the art (e.g., through mild to
moderate chemical cross-linking).
[0037] In certain embodiments, the elongated elements of a tissue
treatment product are further processed to produce elements having
a high aspect ratio. As used herein, a "high aspect ratio" element
is an element having a three dimensional structure (i.e., a length,
a width, and a height), one dimension (i.e., the "long axis") that
is substantially larger than the other two dimensions, and two
remaining dimensions that are substantially smaller than the long
axis and are generally measured in the micrometer to the millimeter
range (e.g., two dimensions of less than 50 mm, 40 mm, 30 mm, 20
mm, 15 mm, 10 mm, 5 mm, 4 mm, 3 mm, 2 mm, 1.5 mm, 1 mm, 900 .mu.m,
800 .mu.m, 700 .mu.m, 600 .mu.m, 500 .mu.m, 400 .mu.m, 300 .mu.m,
200 .mu.m, or 100 .mu.m, or any value in between). The term
"substantially" in this context means having a long axis that is at
least 10% longer than either of the two remaining dimensions. In
some embodiments, the high aspect ratio tissue treatment product is
at least 50%, 55%, 60%, 65%, 70%, 75%, 100%, 150%, 200%, 250%,
300%, 350%, 400%, 450%, 500%, 750%, 1000%, 2000% or 5000% (or any
percentage in between) longer in one dimension.
[0038] For example, high aspect ratio elements can be prepared by
slicing elongated elements parallel to the long axis or across the
face of the two shorter dimensions in order to form thin elements
having a long axis and a high aspect ratio (e.g., thin fibers,
threads, noodles, or other thin strands) of desired dimensions.
(See FIG. 1.) As used herein, "thin" means having two shorter
dimensions that are measured in the micrometer to the millimeter
scale (e.g., two dimensions of less than 50 mm, 40 mm, 30 mm, 20
mm, 15 mm, 10 mm, 5 mm, 4 mm, 3 mm, 2 mm, 1.5 mm, 1 mm, 900 .mu.m,
800 .mu.m, 700 .mu.m, 600 .mu.m, 500 .mu.m, 400 .mu.m, 300 .mu.m,
200 .mu.m, or 100 .mu.m, or any value in between). A high aspect
ratio element prepared by slicing an elongated element can have a
long axis equivalent in length to the long axis or equal in length
to the circumference of an elongated element prior to processing,
or the high aspect ratio elements product can be further processed
(e.g., by manual cutting) to yield a long axis that is shorter than
the full length of the long axis or the circumference of the
original elongated element.
[0039] In certain embodiments, the high aspect ratio elements can
be organized to form a mesh, weave, or other tertiary structure.
For example, high aspect ratio strands can be twined to form a
larger mesh of acellular tissue. As used herein, a "mesh" is any
composition comprising woven or interconnected strands of
biological fibers. One of skill in the art will recognize that the
tightness of the weave or mesh will vary depending on the desired
physical properties of the tertiary structure (e.g., mechanical
strength, porosity, flexibility, etc.). In other embodiments, the
high aspect ratio strands of a tissue treatment product are kept in
a loose concentration (i.e., without an organized tertiary
structure) for ease of separation and/or surgical delivery into an
implant site.
[0040] Tissue treatment products can comprise elements having an
acellular tissue matrix and/or elements having an intact or
partially decellularized tissue matrix. In one embodiment, the
tissue treatment product comprises elements having an acellular
dermal tissue matrix. In certain embodiments, the tissue from which
the acellular or partially decellularized tissue matrix is derived
is selected from one or more of fascia, pericardial tissue, dura,
umbilical cord tissue, placental tissue, cardiac valve tissue,
ligament tissue, tendon tissue, arterial tissue, venous tissue,
neural connective tissue, urinary bladder tissue, ureter tissue,
skin, dermal, subdermal tissue, heart tissue, lung tissue, liver
tissue, and intestinal tissue.
[0041] In various embodiments, a tissue treatment product comprises
elongated elements having a flexible three-dimensional shape that
can conform to the anatomic structure of an implant site. For
example, tissue treatment products can be useful to support breast
implants, e.g., for use in breast augmentation and/or
reconstruction. For example, a tissue treatment product having
elongated or high aspect ratio elements can be placed around a
breast implant and used to fill the space between the implant and
surrounding native tissue, thereby providing a smoother contour
and/or more natural look and feel for the implant. The elongated or
high aspect ratio elements within a tissue treatment product can
either naturally resist migration from their position surrounding
an implant, or they can be attached (e.g., with sutures) to
surrounding fascia, muscle, or other native tissue, thereby helping
to secure an implant in a proper position, to reduce or prevent
scar formation, or to otherwise alter the aesthetic appearance of
an implant.
[0042] Tissue treatment products can be selected to provide a
variety of different biological and mechanical properties. For
example, a tissue treatment product can be selected in order to
provide a scaffold in which native cells from tissue surrounding an
implanted tissue treatment product can migrate and proliferate,
thereby enhancing the speed or overall level of repair,
regeneration, healing, or treatment of native tissue. For example,
an acellular tissue matrix, when implanted on or into fascia, may
be selected to allow for regeneration of the fascia without
excessive inflammation, fibrosis or scar tissue formation (e.g., by
selecting a fully decellularized tissue product). In some
embodiments, the loose, porous structure of an elongated or high
aspect ratio acellular tissue treatment product avoids the
obstruction and subsequent buildup of fluid within the implant
site, while also providing a scaffold for native cells, tissue, and
vasculature to migrate and proliferate. In some embodiments, the
elongated or high aspect ratio acellular tissue treatment products
resist migration away from the implant site.
[0043] In certain embodiments, the elongated or high aspect ratio
tissue treatment products of the present disclosure can be molded
to adapt to any desired three-dimensional structure (e.g., to fill
the anatomical structure of an implant site) without requiring
undesirable chemical alterations in the tissue matrix. In various
embodiments, the elongated or high aspect ratio elements within a
tissue treatment product are capable of substantial stretching,
torsion, or compression. In some embodiments, the elongated or high
aspect ratio elements within a tissue treatment product are capable
of rapidly returning to their original dimensions after the release
of a compression, tension, or torsion force. In some embodiments,
the elongated or high aspect ratio tissue treatment products can be
molded into and maintain a three-dimensional structure without
excessive crosslinking. Although cross-linking may assist in
maintaining a desired three-dimensional shape, excessive
crosslinking can alter the biological properties of tissue
treatment products. In some embodiments, elongated or high aspect
ratio elements are joined to form desired three dimensional
structures (e.g., spheres, columns, or other shapes intended to
match anatomical implant sites) using natural adhesion, or by
freezing, freeze-drying, desiccating, or by any other method of
fixing the three dimensional shape of acellular tissue that is
known in the art (e.g., through mild to moderate chemical
cross-linking)
[0044] Tissue crosslinking can be measured by an increase in the
denaturation temperature of a tissue matrix, as measured with
differential scanning calorimetry. Accordingly, in some
embodiments, tissue treatment products of the present disclosure
include an acellular or partially decellularized tissue matrix that
has a denaturation temperature, as measured by differential
scanning calorimetry, that is within 5.degree. C. (i.e., within
5.degree. C., 4.degree. C., 3.degree. C., 2.degree. C., or
1.degree. C., or any temperature in between) of the denaturation
temperature of the tissue from which the matrix is produced.
[0045] The extracellular matrix within the elements of a tissue
treatment product may consist of collagen, elastin, and/or other
fibers, as well as proteoglycans, polysaccharides and/or growth
factors. In some embodiments, the acellular tissue matrix may
retain some or all of the extracellular matrix components that are
found naturally in a tissue prior to decellularization, or various
undesirable components may be removed by chemical, enzymatic or
genetic means. In general, the acellular matrix provides a
structural network on which native tissue and vasculature can
migrate, grow, and proliferate. The exact structural components of
the extracellular matrix will depend on the tissue selected and the
processes used to prepare the acellular tissue.
[0046] A tissue treatment product can be derived from any tissue
that is suitable for decellularization and subsequent implantation.
Exemplary tissues include, but are not limited to, bone, skin,
dermis, intestine, urinary bladder, tendon, ligament, muscle,
fascia, neurologic tissue, vessel, liver, heart, lung, kidney,
cartilage, and/or any other suitable tissue. In certain
embodiments, the tissue treatment product can include a mammalian
soft tissue. For example, in certain embodiments, the tissue
treatment product can include partially or completely
decellularized mammalian dermis. In other embodiments, the tissue
treatment product can comprise partially or completely
decellularized small intestine submucosa. In certain embodiments,
the decellularized tissue can come from human or non-human sources.
Exemplary, suitable non-human tissue sources include, but are not
limited to, pigs, sheep, goats, rabbits, monkeys, and/or other
non-human mammals.
[0047] In certain embodiments, tissue treatment products can be
formed from ALLODERM.RTM. or STRATTICE.TM., which are human and
porcine acellular dermal matrices respectively (LifeCell Corp.,
Branchburg, N.J.). Alternatively, any other suitable acellular
tissue matrices can be used. For example, a number of biological
scaffold materials are described by Badylak et al., and the methods
of the present disclosure can be used to produce a stable
three-dimensional acellular tissue matrix using any of those
materials, or any other similar materials. Badylak et al.,
"Extracellular Matrix as a Biological Scaffold Material: Structure
and Function," Acta Biomaterialia (2008),
doi:10.1016/j.actbio.2008.09.013, hereby incorporated by reference
in its entirety.
[0048] In certain embodiments, a tissue treatment product lacks
certain undesirable antigens. For example, certain animal tissues
contain alpha-galactose (.alpha.-gal) epitopes that are known to
elicit reactions in humans. Therefore, acellular tissue treatment
products derived from various animal tissues can be produced or
processed to lack certain antigens, such as .alpha.-gal. In some
embodiments, tissue treatment products lack substantially all
.alpha.-gal moieties. Elimination of the .alpha.-gal epitopes from
a tissue treatment product may diminish the immune response against
the composition. U. Galili et al., J. Biol. Chem. 263: 17755
(1988). Since non-primate mammals (e.g., pigs) produce .alpha.-gal
epitopes, xenotransplantation of acellular tissue matrix material
from these mammals into primates may result in rejection because of
primate anti-Gal binding to the .alpha.-gal epitopes on the
acellular tissue matrix. The binding results in the destruction of
the acellular tissue by complement fixation and by
antibody-dependent cell cytotoxicity. U. Galili et al., Immunology
Today 14: 480 (1993); M. Sandrin et al., Proc. Natl. Acad. Sci. USA
90: 11391 (1993); H. Good et al., Transplant. Proc. 24: 559 (1992);
B. H. Collins et al., J. Immunol. 154: 5500 (1995).
[0049] As described in detail below, in various embodiments, tissue
treatment products can be processed to remove antigens such as
.alpha.-gal, e.g., by chemical or enzymatic treatment.
Alternatively, tissue treatment products can be produced from
animals that have been genetically modified to lack these
epitopes.
[0050] In various embodiments, tissue treatment products have
reduced bioburden (i.e., a reduced number of microorganisms growing
on the compositions). In some embodiments, tissue treatment
products lack substantially all bioburden (i.e., the tissue
treatment products are aseptic or sterile). As used herein,
"lacking substantially all bioburden" means tissue treatment
products in which the concentration of growing microorganisms is
less than 1%, 0.1%, 0.01%, 0.001%, or 0.0001% (or any percentage in
between) of that growing on untreated tissue treatment
products.
[0051] In certain embodiments, tissue treatment products are
completely or substantially free of all cells normally present in
the tissue from which the tissue treatment product is derived. As
used herein, "substantially free of all cells" means that the
tissue treatment product contains less than 20%, 10%, 5%, 1%, 0.1%,
0.01%, 0.001%, or 0.0001% (or any percentage in between) of the
cells that normally grow within the acellular matrix of the tissue
prior to decellularization.
[0052] In some embodiments, tissue treatment products can include
partially decellularized tissue matrices and/or decellularized
tissue matrices that have been repopulated with viable cells.
Various cell types can be used for repopulation, including stem
cells such as embryonic stem cells, adult stem cells (e.g.
mesenchymal stem cells), and/or neuronal cells. Any other viable
cells that are histocompatible with the patient in which they are
being implanted can also be used. In some embodiments, the
histocompatible cells are mammalian cells. Such cells can promote
native tissue migration, proliferation, and/or vascularization. In
various embodiments, the viable cells are applied to the acellular
tissue matrix before or after implantation of a tissue treatment
product.
[0053] In certain embodiments, the tissue treatment products
comprises one or more additional agents. In some embodiments, the
additional agent can comprise an anti-inflammatory agent, an
analgesic, or any other desired therapeutic or beneficial agent. In
certain embodiments, the additional agent can comprise, e.g., at
least one added growth or signaling factor (e.g., a cell growth
factor, an angiogenic factor, a differentiation factor, a cytokine,
a hormone, and/or a chemokine). These additional agents can promote
native tissue migration, proliferation, and/or vascularization. In
some embodiments, the growth or signaling factor is encoded by a
nucleic acid sequence contained within an expression vector.
Preferably, the expression vector is in one or more of the viable
cells that can be added, optionally, to a tissue treatment product.
As used herein, the term "expression vector" refers to any nucleic
acid construct that is capable of being taken up by a cell,
contains a nucleic acid sequence encoding a desired protein, and
contains the other necessary nucleic acid sequences (e.g.
promoters, enhancers, initiation and termination codons, etc.) to
ensure at least minimal expression of the desired protein by the
cell.
[0054] Tissue treatment products, as described above, can be
provided in some embodiments in packaged, hydrated, frozen,
freeze-dried, and/or dehydrated form. In certain embodiments, the
packaged tissue treatment products are sterile. In certain
embodiments, the tissue treatment products are provided in a kit,
comprising a packaged tissue treatment product and instructions for
preparing and/or using the tissue treatment products.
Methods of Production
[0055] Disclosed herein are methods of making tissue treatment
products comprising elongated and/or high aspect ratio elements. In
some embodiments, the method comprises selecting a tissue
containing an extracellular collagen matrix; partially or
completely decellularizing the tissue; and applying mechanical
forces to the tissue matrix to produce the elongated or high aspect
ratio elements of the tissue treatment product.
[0056] A tissue treatment product can be prepared from any tissue
that is suitable for decellularization and subsequent implantation.
Exemplary tissues include, but are not limited to, at least one of
bone, skin, adipose, dermis, subdermal tissue, intestine, urinary
bladder, tendon, ligament, muscle, fascia, neurologic tissue,
vessel, liver, heart, lung, kidney, cartilage, and/or any other
suitable tissue. In certain embodiments, the tissues can include a
mammalian soft tissue. For example, in certain embodiments, the
tissue can comprise mammalian dermis. In certain embodiments, the
dermis can be separated from surrounding epidermis and/or other
tissues, such as subcutaneous fat. In certain embodiments, the
tissue can comprise small intestine submucosa. In certain
embodiments, the tissue can include human and/or non-human sources.
Exemplary, suitable non-human tissue sources include, but are not
limited to, pigs, sheep, goats, cow, rabbits, monkeys, and/or other
non-human mammals.
[0057] In some embodiments, a tissue treatment product is prepared
by harvesting and partially or completely decellularizing a donor
tissue. Exemplary methods for decellularizing tissue are disclosed
in U.S. Pat. No. 6,933,326 and U.S. Patent Application No.
2010/0272782, which are hereby incorporated by reference in their
entirety. In some embodiments, the decellularized tissue provides a
porous extracellular scaffold structure into which cells from
surrounding native tissue can migrate and proliferate after
implantation of a tissue treatment product into a host site. In
certain exemplary embodiments, the acellular tissue comprises
ALLODERM.RTM. or STRATTICE.TM., which are acellular human dermal
products and porcine dermal products, respectively, and are
available from LifeCell Corporation (Branchburg, N.J.).
[0058] In various embodiments, the general steps involved in the
production of an acellular tissue matrix include harvesting tissue
from a donor (e.g., a human cadaver or animal source) and removing
cells under conditions that preserve biological and structural
function. In certain embodiments, the harvested tissue can be
washed to remove any residual cryoprotectants and/or other
contaminants. Solutions used for washing can be any
physiologically-compatible solution. Examples of suitable wash
solutions include distilled water, phosphate buffered saline (PBS),
or any other biocompatible saline solution.
[0059] In certain embodiments, the decellularization process
includes chemical treatment to stabilize the harvested tissue so as
to avoid biochemical and structural degradation before, during, or
after cell removal. In various embodiments, the stabilizing
solution arrests and prevents osmotic, hypoxic, autolytic, and/or
proteolytic degradation; protects against microbial contamination;
and/or reduces mechanical damage that can occur during
decellularization of tissues that contain, for example, smooth
muscle components (e.g., blood vessels). The stabilizing solution
may contain an appropriate buffer, one or more antioxidants, one or
more oncotic agents, one or more antibiotics, one or more protease
inhibitors, and/or one or more smooth muscle relaxants.
[0060] In various embodiments, the tissue is then placed in a
decellularization solution to remove viable cells (e.g., epithelial
cells, endothelial cells, smooth muscle cells, and fibroblasts,
etc.) from the extracellular matrix without damaging the biological
and/or structural integrity of the extracellular matrix. The
decellularization solution may contain an appropriate buffer, salt,
an antibiotic, one or more detergents (e.g., TRITON X-100.TM.,
sodium dodecyl sulfate, sodium deoxycholate, polyoxyethylene (20)
sorbitan mono-oleate, etc.), one or more agents to prevent
cross-linking, one or more protease inhibitors, and/or one or more
enzymes. In some embodiments, the decellularization solution
comprises 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 1.0%, 1.5%, 2.0%, 2.5%,
3.0%, 3.5%, 4.0%, 4.5%, or 5.0% (or any percentage in between) of
TRITON X-100.TM. and, optionally, 10 mM, 15 mM, 20 mM, 25 mM, 30
mM, 35 mM, 40 mM, 45 mM, or 50 mM EDTA (ethylenediaminetetraacetic
acid) (or any concentration in between). In some embodiments, the
tissue is incubated in the decellularization solution at 25, 30,
31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, or 42.degree. C. (or
any temperature in between), and optionally with gentle shaking at
10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150
rpm (or any rpm in between). The incubation can be for 1, 2, 3, 4,
5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 24, 36, or 48 hours (or any time
in between). The length of time or concentration of detergent can
be adjusted in order to partially or more fully decellularize the
tissue. In certain embodiments, additional detergents may be used
to remove fat from the tissue sample. For example, in some
embodiments, 1, 2, 3, 4, or 5% sodium deoxycholate (or any
percentage in between) is added to the decellularization solution
in order to remove fat from the tissue.
[0061] In some embodiments, after decellularization, the tissue
sample is washed thoroughly. Any physiologically-compatible
solutions can be used for washing. Examples of suitable wash
solutions include distilled water, phosphate buffered saline (PBS),
or any other biocompatible saline solution. In certain embodiments,
e.g., when xenogenic material is used, the decellularized tissue is
then treated overnight at room temperature with a deoxyribonuclease
(DNase) solution. In some embodiments, the tissue sample is treated
with a DNase solution prepared in DNase buffer (20 mM HEPES
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 20 mM
CaCl.sub.2 and 20 mM MgCl.sub.2). Optionally, an antibiotic
solution (e.g., Gentamicin) may be added to the DNase solution. Any
suitable DNase buffer can be used, as long as the buffer provides
for suitable DNase activity.
[0062] While an acellular tissue matrix may be derived from tissue
from one or more donor animals of the same species as the intended
recipient animal, this is not necessarily the case. Thus, for
example, an acellular tissue matrix may be derived from porcine
tissue and implanted in a human patient. Species that can serve as
donors and/or recipients of acellular tissue matrices include,
without limitation, mammals, such as humans, nonhuman primates
(e.g., monkeys, baboons, or chimpanzees), pigs, cows, horses,
goats, sheep, dogs, cats, rabbits, guinea pigs, gerbils, hamsters,
rats, or mice.
[0063] In certain embodiments, decellularized tissue can be treated
with one or more enzymes to remove undesirable antigens, e.g., an
antigen not normally expressed by the recipient animal and thus
likely to lead to an immune response and/or rejection of the
implanted tissue treatment product. For example, in certain
embodiments, decellularized tissue can be treated with
alpha-galactosidase to remove alpha-galactose (.alpha.-gal)
moieties. In some embodiments, to enzymatically remove .alpha.-gal
epitopes, after washing tissue thoroughly with saline, the tissue
may be subjected to one or more enzymatic treatments to remove
.alpha.-gal antigens, if present in the sample. In certain
embodiments, the tissue may be treated with an
.alpha.-galactosidase enzyme to eliminate .alpha.-gal epitopes. In
one embodiment, the tissue is treated with .alpha.-galactosidase at
a concentration of 0.2 U/ml prepared in 100 mM phosphate buffered
saline at pH 6.0. In other embodiments, the concentration of
.alpha.-galactosidase is reduced to 0.1 U/ml or increased to 0.3,
0.4, or 0.5 U/ml (or any value in between). In other embodiments,
any suitable enzyme concentration and buffer can be used, as long
as sufficient antigen removal is achieved. In addition, certain
exemplary methods of processing tissues to reduce or remove
alpha-1,3-galactose moieties are described in Xu et al., Tissue
Engineering, Vol. 15, 1-13 (2009), which is hereby incorporated by
reference in its entirety.
[0064] In certain embodiments, animals that have been genetically
modified to lack one or more antigenic epitopes may be selected as
the tissue source for a tissue treatment product. For example,
animals (e.g., pigs) that have been genetically engineered to lack
the terminal .alpha.-galactose moiety can be selected as the tissue
source. For descriptions of appropriate animals and methods of
producing transgenic animals for xenotransplantation, see U.S.
patent application Ser. No. 10/896,594 and U.S. Pat. No. 6,166,288,
which are hereby incorporated by reference in their entirety.
[0065] In some embodiments, the decellularized tissue can be
treated to reduce bioburden (i.e., to reduce the number of
microorganisms growing on the tissue). In some embodiments, the
tissue is treated such that it lacks substantially all bioburden
(i.e., the tissue is aseptic or sterile). As used herein,
"substantially all bioburden" means that the concentration of
microorganisms growing on the tissue is less than 1%, 0.1%, 0.01%,
0.001%, or 0.0001% of that growing on untreated tissue, or any
percentage in between. Suitable bioburden reduction methods are
known to one of skill in the art, and may include exposing the
tissue treatment product to radiation. Irradiation may reduce or
substantially eliminate bioburden. In some embodiments, an absorbed
dose of 15-17 kGy of E-beam radiation is delivered in order to
reduce or substantially eliminate bioburden. In various
embodiments, the amount of radiation to which the tissue treatment
product is exposed can be between 5 Gy and 50 kGy. Suitable forms
of radiation can include gamma radiation, e-beam radiation, and
X-ray radiation. Other irradiation methods are described in U.S.
Application No. 2010/0272782, the disclosure of which is hereby
incorporated by reference in its entirety.
[0066] In certain embodiments, after the acellular tissue matrix is
formed, histocompatible, viable cells may optionally be seeded in
the acellular tissue matrix. In some embodiments, histocompatible
viable cells may be added to the matrices by standard in vitro cell
co-culturing techniques prior to transplantation, or by in vivo
repopulation following transplantation. In vivo repopulation can be
by the migration of native cells from surrounding tissue into the
acellular tissue matrix or by infusing or injecting histocompatible
cells obtained from the recipient or from another donor into the
acellular tissue matrix in situ. Various cell types can be used,
including stem cells such as embryonic stem cells and/or adult stem
cells (e.g. mesenchymal stem cells). Any other viable cells that
are histocompatible with the patient in which they are being
implanted can also be used. In some embodiments, the
histocompatible cells are mammalian cells. Such cells can promote
native tissue migration, proliferation, and/or vascularization. In
various embodiments, the cells can be directly applied to the
acellular tissue matrix just before or after implantation.
[0067] In certain embodiments, one or more additional agents can be
added to the acellular tissue matrix. In some embodiments, the
additional agent can comprise an anti-inflammatory agent, an
analgesic, or any other desired therapeutic or beneficial agent. In
certain embodiments, the additional agent can comprise at least one
added growth or signaling factor (e.g., a cell growth factor, an
angiogenic factor, a differentiation factor, a cytokine, a hormone,
and/or a chemokine). These additional agents can promote native
tissue migration, proliferation, and/or vascularization. In some
embodiments, the growth or signaling factor is encoded by a nucleic
acid sequence contained within an expression vector. Preferably,
the expression vector is in one or more of the viable cells that
can be included, optionally, along with the acellular tissue
matrix. As used herein, the term "expression vector" refers to any
nucleic acid construct that is capable of being taken up by a cell,
contains a nucleic acid sequence encoding a desired protein, and
contains the other necessary nucleic acid sequences (e.g.
promoters, enhancers, termination codon, etc.) to ensure at least
minimal expression of the desired protein by the cell.
[0068] In various embodiments, either before or after
decellularization, the acellular tissue matrix can be shaped and/or
processed into a desired form, such as an elongated structure.
Accordingly, a method is provided for shaping an acellular tissue
matrix. In some embodiments, acellular tissue can be rolled,
packed, folded, compressed or otherwise molded into a desired
shape, such as a ball, cube, cylinder, ellipsoid, rectangular
cuboid, or any other regular or irregular shape. One or more
separate pieces of acellular tissue (e.g., 1, 2, 3, 4, 5, 10, or
more pieces) can be incorporated into the desired shape. For
example, one or more pieces of acellular tissue (e.g., 1, 2, 3, 4,
5, 10, or more pieces) can be rolled into a cylinder or into a
similar elongated shape in order to form an elongated element of a
tissue treatment product. The rolled tissue can retain its shape by
natural adhesion, or by freezing, freeze-drying, desiccating, or by
any other method of fixing the acellular tissue that is known in
the art (e.g., through mild to moderate chemical cross-linking)
[0069] In certain embodiments, the elongated elements of a tissue
treatment product can be further processed to produce elements
having a high aspect ratio. For example, the elongated elements can
be sliced (e.g., using a knife, deli slicer, grater, etc.) parallel
to their long axis or across the face of their two smaller
dimensions in order to form thin elements having a long axis and a
high aspect ratio (e.g., a "noodle" structure). As used herein, a
high aspect ratio means having two dimensions that are measured in
the micrometer to the millimeter scale (e.g., two dimensions of
less than 50 mm, 40 mm, 30 mm, 20 mm, 15 mm, 10 mm, 5 mm, 4 mm, 3
mm, 2 mm, 1 mm, 900 .mu.m, 800 .mu.m, 700 .mu.m, 600 .mu.m, 500
.mu.m, 400 .mu.m, 300 .mu.m, 200 .mu.m, or 100 .mu.m, or any value
in between). The high aspect ratio elements of a tissue treatment
product produced in this way can have a long axis equivalent to the
length of the circumference or long axis of an elongated element
product prior to slicing, or the high aspect ratio elements can be
further processed (e.g., by manual cutting) to yield a long axis
that is shorter than the full length of the long axis or
circumference of the original elongated elements. In some
embodiments, the long axis of the high aspect ratio element has a
dimension that is at least 50% longer than either of the two
remaining dimensions. In some embodiments, the high aspect ratio
element is at least about 50%, 55%, 60%, 65%, 70%, 75%, 100%, 150%,
200%, 250%, 300%, 350%, 400%, 450%, 500%, 750%, 1000%, 2000% or
5000% (or any percentage in between) longer in one dimension.
[0070] In some embodiments, elongated cylindrical elements
containing one or more pieces or sheets of rolled and frozen
acellular tissue are sliced (e.g., using a knife, deli slicer,
grater, etc.) to form the high aspect ratio elements of a tissue
treatment product. The slicing can be done at a desired thickness
to produce high aspect ratio elements of desired dimensions. In
some embodiments, the high aspect ratio elements can have a long
axis equivalent to the length of the circumference of the frozen
cylindrical elements. In other embodiments, the high aspect ratio
elements can be cut (e.g., using a knife, scalpel, or other blade)
such that their long-axis length is shortened.
[0071] In certain embodiments, a device for slicing, such as a deli
slicer, is used to slice across the circular face of a cylinder of
rolled acellular tissue, thereby producing high aspect ratio
elements (e.g., "noodles") of predetermined thickness, where the
thickness depends on the thickness setting of the device used to
slice the cylinder. In some embodiments, the cylinder of rolled
acellular tissue is frozen to allow for easier slicing (e.g., to
allow for more consistent slicing).
[0072] In certain embodiments, the high aspect ratio elements of a
tissue treatment product can be further processed to form a mesh,
weave, or other tertiary structure. For example, high aspect ratio
strands can be twined to form a larger mesh of acellular tissue. As
used herein, a "mesh" is any composition comprising woven or
interconnected strands of biological fibers. One of skill in the
art will recognize that the tightness of the weave or mesh can vary
depending on the desired physical properties of the tertiary
structure (e.g., mechanical strength, porosity, flexibility, etc.)
In some embodiments, the tertiary structure is held together by
natural adhesion, or by freezing, freeze-drying, desiccating, or by
any other method of fixing the acellular tissue that is known in
the art (e.g., through mild to moderate chemical cross-linking). In
other embodiments, the high aspect ratio elements of a tissue
treatment product are kept in a loose concentration (i.e., without
an organized tertiary structure) for ease of separation and/or
surgical delivery into an implant site.
Methods of Use
[0073] An objective when using tissue-derived products to
regenerate, repair, heal, or otherwise treat diseased or damaged
tissues and organs is to provide an implant capable of maintaining
shapes or configurations that more closely conform to the anatomic
structures that are being treated, while also reducing or avoiding
implant migration away from the implant site. Accordingly,
disclosed in certain embodiments are methods of using tissue
treatment products comprising collections of elongated or high
aspect ratio elements as fillers to pack a void space, wound, or
other tissue in need of treatment, repair, healing, or
regeneration. As used herein, a "collection" means at least 2
pieces or elements (e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15,
20, 25, 30, 35, 40, 45, 50, 75, or 100 pieces, or any number in
between). The individual pieces of tissue within the collection can
have the same or different structures. The tissue treatment product
comprising a collection of elongated or high aspect ratio tissue
matrices can be molded to fill a desired shape while reducing the
risk that the implant will migrate away from the implant site. In
some embodiments, the tissue treatment product can also be used for
cosmetic or enhancement purposes (e.g., as a cosmetic implant or as
an adjunct to a traditional cosmetic implant).
[0074] In certain embodiments, following the creation of space
between tissue planes as a result of disease, trauma, or surgical
intervention, a tissue treatment product comprising one or a
collection of elongated or high aspect ratio elements is placed
between the separated tissue planes. In certain embodiments, the
implanted tissue treatment product can be used to completely fill
and conform to the shape of a space in a host tissue. In some
embodiments, the product can be folded, compressed, or otherwise
molded to fill the anatomical space of an implant site.
[0075] In certain embodiments, the elements of an implanted tissue
treatment product can have an organized tertiary structure, such as
a mesh, weave or other organized structure, or the elements can be
present in a loose form lacking an organized tertiary structure. In
some embodiments, the tissue treatment products can be folded,
compressed, packed, or otherwise molded to fill the space between
separated tissue planes, regardless of the shape of the space
(e.g., an irregularly shaped wound can be filled with a tissue
treatment product until all space within the wound is filled with
tissue treatment product). In one example, the implanted tissue
treatment product comprises elements having a high aspect ratio. In
certain embodiments, the high aspect ratio elements can be folded,
compressed, or otherwise molded within an implant site until all
void space in the implant site is filled. In some embodiments, the
high aspect ratio elements can also be organized in a mesh, weave
or other organized tertiary structure.
[0076] In some embodiments, a tissue treatment product can be used
for tissue bulking (e.g., to fill space surrounding a breast
implant or as supporting material between bone and cartilage or in
the submucosal layer of the nasal passage following otolaryngology
surgery). In other embodiments, tissue treatment products are used
to completely fill void space (e.g., after tumor removal), to bulk
native tissue (e.g., for nasal reconstruction), or for aesthetic
tissue enhancement purposes (e.g., as a complement to breast
implants that is used to smooth contours and fill space surrounding
the implant).
[0077] In certain embodiments, a tissue treatment product is
implanted in a host tissue and remains in place through the natural
tendency of the elongated or high aspect ratio elements to resist
migration away from the implant site. In other embodiments, tissue
treatment products are secured to the native tissue planes that
surround an implant site using any known method that results in the
temporary or permanent physical association of the tissue treatment
products with the proximate tissue. For example, biodegradable
sutures can be used to physically secure the tissue treatment
product to the surrounding native tissue. Alternatively, external
positive pressure (e.g., a dressing or binding around the implant
site) can be applied to compress the surrounding native tissue and
maintain the native tissue in contact with the implanted tissue
treatment products, thereby preventing migration of the tissue
treatment products away from the implant site.
[0078] One benefit of implanting a tissue treatment product
comprising a collection of elongated or high aspect ratio elements
is that the elongated or high aspect ratio structure of these
elements can prevent or reduce the tendency of an implant to
migrate away from the implant site. Thus, in some embodiments,
tissue treatment products can be used without requiring undesirable
chemical modification or physical attachment to native tissue that
is otherwise necessary in order to prevent migration away from an
implant site. In various embodiments, the ability to retain a
tissue treatment product at an implant site without requiring
chemical or physical intervention (e.g., cross-linking or suturing)
can be important when using a tissue treatment product to fill void
space (e.g., after tumor removal), to bulk native tissue (e.g., for
nasal reconstruction), or for aesthetic tissue enhancement purposes
(e.g., as a complement to breast implants that is used to smooth
contours and fill space surrounding the implant). In these
contexts, tissue treatment products can be implanted and will not
migrate from the implant site, while still avoiding the irritation
or loss of biocompatibility associated with chemical or physical
processing to secure an implant to surrounding tissue.
[0079] In certain embodiments, a tissue treatment product
comprising a collection of high aspect ratio elements (e.g.,
"noodles") is used. The flexible strands of the high aspect ratio
tissue treatment products can be folded, compacted, and/or molded
to fill an implant site. The high aspect ratio elements allow for
continued fluid mobility within the implant site, thereby
preventing undesirable fluid accumulation. At the same time, the
high aspect ratio elements provide an acellular scaffold in which
native cells and vasculature can migrate and proliferate, thereby
promoting or enhancing tissue repair, regeneration, and/or healing.
Also, the high aspect ratio structure of the elements can prevent
the tissue treatment product from migrating away from the implant
site, without requiring the use of chemical cross-linking agents or
other interventions designed to immobilize the tissue treatment
product. For example, tissue treatment products comprising a
collection of high aspect ratio elements can be used to fill the
space surrounding a breast implant. The high aspect ratio tissue
treatment products can be used in this context to support the
breast implant and keep the implant from shifting from the
appropriate location, while also providing a more natural look and
feel to the implant by filling the space between the breast implant
and surrounding tissue, for example by avoiding and/or reducing
inflammation, or the formation of granulation or scar tissue
surrounding the implant that could result in an undesirably
hardened or raised implant. In another example, the high aspect
ratio tissue treatment products can be used to pack a wound or
other space between separated tissues resulting from disease,
damage, or surgical intervention.
[0080] In some embodiments, use of a tissue treatment product
comprising a collection of elongated or high aspect ratio elements
can result in an implant that has increased persistence in the site
of implantation, as compared to implanted sheets of acellular
tissue. Persistence refers to the volume of implanted material that
remains at a site of implantation over time. Persistence can be
measured in various ways that will be familiar to one of skill in
the art. For example, persistence of the tissue treatment product
at the site of implantation can be measured using ultrasound in
order to calculate the volume of tissue treatment product remaining
at an implant site over time.
[0081] In some embodiments, use of a tissue treatment product
comprising a collection of elongated or high aspect ratio elements
can result in an implanted tissue treatment product that has
improved biomechanical properties, as compared to implanted sheets
of acellular tissue. Biomechanical properties can be evaluated in
various ways that will be familiar to one of skill in the art. For
example, the softness of an implant over time can be evaluated by
looking at the tonometry of the implant (i.e., the level of
displacement that occurs when the implant is placed under load).
For example, indentation tonometry can be used, involving the
measurement of the depth of indentation produced by a rod of known
weight when placed above the site of implantation. A larger
indentation value indicates a softer implant site, while a lower
value indicates a harder site. Likewise, in another example the
stiffness of the implant over time can be evaluated using the
BTC-2000.TM. (SRLI Technologies, Nashville, Tenn.), which can be
used to measure stiffness and other biomechanical properties of
skin and underlying soft tissue. In some embodiments, an implanted
tissue treatment product comprising a collection of elongated or
high aspect ratio elements can result in a firmer implant site, as
compared to surrounding tissue.
[0082] In certain embodiments, high aspect ratio tissue treatment
products that have been organized to form a mesh, weave, or other
tertiary structure are implanted in a host tissue. The mesh, weave,
or other tertiary structure can be used to fill the site of
implantation. For example, a mesh can be used to pack a wound or
other space between separated tissues resulting from disease,
damage, or surgical intervention. The flexible mesh can be
compacted to more tightly fill a space between separated tissues or
can be used to provide structural support and reinforcement for a
tissue following removal of native tissue from the site of
implantation. For example, following tumor removal, a mesh or woven
tissue treatment product can be used to fill the space left after
surgical intervention and to reinforce the structure of the
remaining tissue at the site of implantation. For example,
following breast surgery (e.g., lumpectomy), a mesh or woven tissue
treatment product can be implanted to preserve the structural
appearance and feel of the breast, and to promote native tissue
regeneration. In certain embodiments, the mesh, weave, or other
tertiary structure allows for continued fluid mobility within the
implant site, thereby preventing undesirable fluid accumulation. At
the same time, the mesh, weave, or other tertiary structure
provides an acellular scaffold in which native cells and
vasculature can migrate and proliferate, thereby promoting or
enhancing tissue repair, regeneration, and/or healing. Also, in
some embodiments, the mesh structure prevents the tissue treatment
product from migrating away from the site of implantation; the use
of chemical cross-linking agents or other interventions to
immobilize the tissue treatment product may not be required in
these embodiments.
[0083] In various embodiments, a tissue treatment product
comprising a collection of elongated or high aspect ratio elements
is used after surgical removal of a tumor. In some embodiments, the
tumor is a breast tumor. In other embodiments, the tumor is an
abdominal or dermal tumor, or any other tumor for which surgical
removal is indicated and subsequent replacement with a tissue
filler is desirous. In various embodiments, the tissue treatment
products are used to fill the space left by surgical removal of a
tumor. The tissue treatment products can be used, in some
embodiments, to fill the space left by tumor removal while also
allowing for continued fluid mobility within the implant site,
thereby preventing undesirable fluid accumulation. At the same
time, the tissue treatment products provide an acellular scaffold
in which native cells and vasculature can migrate and proliferate,
thereby promoting or enhancing tissue repair, regeneration, and/or
healing. Also, in certain embodiments, the elongated or high aspect
ratio structure of the elements within a tissue treatment product
can prevent the tissue treatment product from migrating away from
the site of implantation; the use of chemical cross-linking agents
or other interventions to immobilize the tissue treatment products
is not required in these embodiments.
[0084] In certain embodiments, a tissue treatment product
comprising a collection of elongated or high aspect ratio elements
is used to fill a space between separated tissue planes that
results from surgical intervention, disease, or trauma. For
example, the tissue treatment products can be used to fill a wound
or to pack the space between tissue planes that have been separated
during surgery. The tissue treatment products provide an acellular
scaffold in which native cells and vasculature can migrate and
proliferate, thereby promoting or enhancing tissue repair,
regeneration, and/or healing. At the same time, the tissue
treatment products allow for continued fluid mobility within the
implant site, thereby preventing undesirable fluid accumulation.
Also, the elongated or high aspect ratio structure of the
collection of elements within a tissue treatment product prevents
the tissue treatment product from migrating away from the site of
implantation; the use of chemical cross-linking agents or other
interventions to immobilize the tissue treatment product is not
required in these embodiments.
[0085] In various embodiments, tissue treatment products comprising
a collection of elongated or high aspect ratio elements are used
for aesthetic purposes. For example, the tissue treatment products
can be used alone or in conjunction with additional implant
materials to enhance or alter the shape, texture, softness,
elasticity, rigidity, contours, or other properties of tissue in
the breast, lips, nose, buttocks, or any other tissue. For example,
tissue treatment products can be used to fill the space between a
traditional breast implant and surrounding tissue in order to
provide a more natural look and feel while preventing fluid
accumulation in the empty space around the implant. Likewise, in
certain embodiments, tissue treatment products can be used to fill
the space between a traditional implant and surrounding tissue in
order to support and anchor the traditional implant and prevent it
from moving or distorting after implantation. In some embodiments,
the tissue treatment products can also promote native tissue
repair, regeneration, and/or healing around a traditional implant
by providing an acellular scaffold in which native cells and
vasculature can migrate and proliferate. In some embodiments, the
implanted tissue treatment products do not interfere with clinical
mammography.
EXAMPLES
[0086] The following examples serve to illustrate, and in no way
limit, the present disclosure.
Example 1a
Preparation of Tissue Treatment Products
[0087] Approximately 500 g of porcine acellular dermal tissue
(PADM) sheets were rinsed and washed and then treated with PRTM
Freeze solution at a 5:1 solution to tissue ratio for 6 hours to 36
hours. The acellular porcine dermal tissue sheets were then rolled
into a cylinder and placed at -80.degree. C. overnight. A deli
slicer was assembled inside a clean room and thoroughly cleaned
using Spor-Klenz and 70% IPA.
[0088] A sharp and clean deli slicer was used to slice frozen PADM.
To keep the deli slicer cold, liquid nitrogen gas was allowed to
flow behind the deli slicer's cutting blade. The frozen cylinder of
acellular tissue was placed inside a container to help in handling
during cutting, and was sliced on the deli slicer to produce tissue
treatment products having a high aspect ratio, e.g., a shape
similar to a "noodle." The circular face of the rolled cylinder of
frozen tissue was kept flat and the cylinder was kept perpendicular
to the slicer's cutting blade. The thickness of the high aspect
ratio tissue produced in this manner could be varied by altering
the deli slicer setting. The deli slicer was set to 1.5 mm diameter
depth and rolled cylinders of tissue were sliced individually or
bundles of rolled cylinders were sliced together.
[0089] After slicing, half the noodles were washed in a
preservative solution and the other half in PBS. Noodles were
washed twice in each solution for 2 hours. Each wash was in a 5:1
solution to tissue ratio, agitated at 100 rpm. Washed noodles were
stored at 4.degree. C.
[0090] Hydrated noodles were weighed out and aseptically packed
inside a syringe. For bioburden testing, half the contents of the
syringe was extruded into a sterile bag, with the remaining half
retained in the syringe and saved for sterilization and
implantation. The syringes were placed in foil-to-foil pouches for
sterilization and were E-beam irradiated at 15.9-21.5 kGy.
Example 1b
Preparation of Tissue Treatment Products
[0091] STRATTICE.TM. (LifeCell Corp.) was preconditioned by hand
cutting into 2 inch by 2 inch samples. Samples were passed through
bench top meat grinder with 5/16 inch cutter setting, then passed a
second time through the grinder with a 3/16 inch setting. Tissue
was sent to Sympak Group (Mandelein, Ill.) for further
micro-cutting using 0.35 and 0.9 mm cut settings. The final cut
tissue tended to clump and formed longer "fibers" when rolled
together.
Example 2
Yucatan Minipig Mammary Gland Testing
[0092] Yucatan minipig mammary glands were used to simulate
clinical lumpectomy and to test and compare different implanted
tissue treatment products used in vivo to treat lumpectomy defects.
Four 20 cc defects per animal were created using electrocautery.
Each defect was filled with one of six different tissue treatment
products comprising PADM tissue filler materials (noodles in PBS,
noodles in a preservative solution, fiber putty in PBS, fiber putty
in a preservative solution, consolidated fiber strands (CFS) and
acellular sheets of STRATTICE.RTM.) or left unfilled. The Yucatan
minipig mammary gland lumpectomy model shared several similarities
with clinical lumpectomy, including the hardening of unrepaired and
reconstructed defects, dimpling of unreconstructed defects, and a
raised appearance to many of the reconstructed defects.
[0093] The surgical techniques used in these experiments resulted
in the production of significant granulation tissue. Granulation
tissue was observed for all surgical implantation sites, including
empty voids (e.g., sites where tissue was removed but no implant
was used to fill the void space). In contrast, implantation of
tissue treatment products without surgical void creation resulted
in little evidence of granulation tissue, as compared to the same
material when implanted in a prepared void. This suggests that
tissue treatment products themselves are not the main cause of
granulation tissue in these experiments.
[0094] The implanted tissue treatment products were evaluated for
persistence, biomechanics, biologic response, and interference with
mammography. The implant characteristics were evaluated at three
time points (0, 4, and 12 weeks). Implants generally persisted, as
evidenced by a lack of dimpling, gross appearance, and ultrasound
data. Persistence was measured by ultrasound and dimple depth.
Biomechanics was evaluated by measuring the displacement of
implanted tissue treatment product when placed under load
(tonometry), by using BTC-2000.TM. (SRLI Technologies, Nashville,
Tenn.) to measure the stiffness and other biomechanical properties
of skin and underlying soft tissue, and, for putty implants, by
rheology (tissue viscosity). Biologic response was evaluated by
histology. Interference with mammography was evaluated by X-ray
imaging.
[0095] Ultrasound was used to evaluate implant volume for the six
different implanted tissue treatment products four weeks after
implantation. Transverse and longitudinal images were acquired for
each implant site, and volume was calculated as 4/3.pi.abc. FIG. 2
shows the calculated ultrasound volume for each of the different
implants four weeks after implantation. FIG. 3 is a plot of
ultrasound volume against dry tissue mass for the various implants,
measured four weeks after implantation. Calibration of ultrasound
calculations was performed by comparing the calculated ultrasound
volume at time T=0 with the actual volumes of implanted material.
(FIG. 4.) Calibration analysis illustrated that ultrasound tends to
underestimate implant volume and had considerable between and
within site variability. Thus, while ultrasound volume is suitable
for trending purposes, it is not suitable for quantification or for
detecting small differences between implants. FIG. 16 provides a
comparison of ultrasound volume for the different implants at four
weeks and twelve weeks after implantation. Significant volume is
lost for all implants except CFS.
[0096] Indentation tonometry (i.e., measuring displacement under
load) was used to evaluate the biomechanical properties of
implanted tissue treatment product. A 0.5 inch, 176 gram rod was
placed over each implant site and the depth of rod penetration was
measured. A larger value indicates a softer (more compliant)
implant site, while a lower value indicates a harder (less
compliant) implant site. FIG. 5 illustrates the results of
indentation tonometry assays on the various implanted tissue
treatment products 4 weeks after implantation. FIG. 6 compares
indentation tonometry results at time T=0 and T=4 weeks for each
tissue treatment product. All tissue treatment products became less
compliant after 4 weeks, as measured by indentation tonometry.
These quantitative results were confirmed by manual palpation. Due
to implant dimpling at 12 weeks, tonometry data was inconsistent
and therefore not reported except for CFS implants and putty
implants in a preservative solution that did not dimple (not
shown).
[0097] To further evaluate the biomechanical properties of
implanted tissue treatment products, BTC-2000.TM. (SRLI
Technologies, Nashville, Tenn.) was used to measure the stiffness
of tissue implants at the time of implantation and after 4 weeks.
BTC-2000 can be used for quantitative and sensitive analyses of the
biomechanical properties of skin and soft tissues, as well as the
intact and/or disruptive characteristics of elastic materials. FIG.
7 indicates that implant stiffness decreased at 4 weeks compared to
pre-surgery. This is in contrast to the increased stiffness over
time observed by indentation tonometry.
[0098] Finally, the impact of implanted tissue treatment products
on tissue contour was evaluated by measuring dimple depth for
sunken implant sites, as well as by photographic observation of
raised implant sites. FIG. 8 is a representative example of a
raised site. Such sites were estimated to be raised by 5-10 mm.
Dimple depth was measured using non-load tonometry. A 176 g rod was
used to measure dimple depth while the rod's weight was supported
from above so that the measurement would not incorporate additional
depth due to the displacement or compression of the tissue under
load. FIG. 9 is a plot of dimple depth at four weeks, as measured
by non-load tonometry, for the various implanted tissue treatment
products, including implanted noodles. FIG. 17 is a comparison of
raised or dimpled implants at 4 weeks and 12 weeks for each implant
type.
[0099] In order to evaluate the potential for implanted tissue
treatment products to interfere with mammography, Yucatan minipig
mammary glands were imaged by 70 KV X-ray before surgery and 4
weeks after implantation of a noodle tissue treatment product (FIG.
10A and FIG. 10B, respectively). No differences in tissue density
between implant site and surrounding tissue were detected by X-ray
following noodle implantation. However, the 70 KV energy used in
this experiment was higher than the 15-52 KV normally used in
mammography, which may have prevented detection of differences in
tissue density.
[0100] To evaluate the biologic response to implanted tissue
treatment products, including implanted noodles, gross observation
was recorded and histology was performed four weeks and twelve
weeks after implantation.
[0101] After four weeks, gross observations were recorded
photographically for implanted noodles in PBS and implanted noodles
in a preservative solution. (See FIGS. 11 and 12, respectively.)
Histology was performed with hematoxylin and eosin (H&E)
staining to evaluate fibroblast repopulation, inflammation, and
revascularization. FIGS. 13 and 14 show H&E staining for
implanted noodles in PBS and in a preservative solution,
respectively. FIG. 15 shows histology scoring of H&E stained
tissue for fibroblasts (FIG. 15A), revascularization (FIG. 15B),
and inflammation (FIG. 15C). Histology scoring was conducted on
stained samples from various tissue treatment products, including
implanted noodles, four weeks after implantation.
[0102] After twelve weeks, implanted noodles in PBS demonstrated
significant fibroblast repopulation and mild revascularization.
There was also a moderate inflammatory response, as evidenced by
the presence of lymphocytes, macrophages, and giant cells. Dense
connective tissue was observed between the implanted noodles (FIG.
18). For noodles in a preservation solution, significant fibroblast
repopulation and moderate revascularization was again observed. A
mild inflammatory response was observed. Dense connective tissue
was observed between the implanted noodles (FIG. 19). FIG. 20 shows
histology scoring of H&E stained tissue for fibroblasts (FIG.
20A), revascularization (FIG. 20B), and inflammation (FIG. 20C) at
four weeks and twelve weeks after implantation.
[0103] The preceding examples are intended to illustrate and in no
way limit the present disclosure. Other embodiments of the
disclosed devices and methods will be apparent to those skilled in
the art from consideration of the specification and practice of the
devices and methods disclosed herein.
* * * * *